Evidence map›Paper›PMID 36004071›Full record

ArticleJTCVS open2021

Therapeutic potential of clinical-grade human induced pluripotent stem cell-derived cardiac tissues.

Hiroaki Osada, Masahide Kawatou, Daiki Fujita, Yasuhiko Tabata, Kenji Minatoya, Jun K Yamashita, Hidetoshi Masumoto

Open access · goldAbstract read
In one paragraph

Article in JTCVS open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hiroaki OsadaDepartment of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masahide KawatouDepartment of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Daiki FujitaiHeart Japan Corporation, Kyoto, Japan.
Yasuhiko TabataDepartment of Biomaterials, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Kenji MinatoyaDepartment of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Jun K YamashitaDepartment of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Hidetoshi MasumotoDepartment of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPRIKEN Center for Biosystems Dynamics Research · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To establish a protocol to prepare and transplant clinical-grade human induced pluripotent stem cell (hiPSC)-derived cardiac tissues (HiCTs) and to evaluate the therapeutic potential in an animal myocardial infarction (MI) model. Methods: We simultaneously differentiated clinical-grade hiPSCs into cardiovascular cell lineages with or without the administration of canonical Wnt inhibitors, generated 5- layer cell sheets with insertion of gelatin hydrogel microspheres (GHMs) (HiCTs), and transplanted them onto an athymic rat MI model. Cardiac function was evaluated by echocardiography and cardiac magnetic resonance imaging and compared with that in animals with sham and transplantation of 5-layer cell sheets without GHMs. Graft survival, ventricular remodeling, and neovascularization were evaluated histopathologically. Results: The administration of Wnt inhibitors significantly promoted cardiomyocyte (CM) ( Conclusions: Transplantation of HiCTs generated from clinical-grade hiPSCs exhibited a prominent therapeutic potential in a rat MI model and may provide a promising therapeutic strategy in cardiac regenerative medicine.

Indexed as

3D, 3-dimensionalcardiac regenerative therapyCM, cardiomyocytecTnT, cardiac isoform of troponin TCUBIC, clear, unobstructed brain imaging cocktails and computational analysis sampleEC, endothelial cellESC, embryonic stem cellFBS, fetal bovine serumFS, fractional shorteningGHM, gelatin hydrogel microsphereGMP, good manufacturing protocolheart failureHiCT, human induced pluripotent stem cell–derived cardiac tissuehiPSC, human induced pluripotent stem cellHLA, human leukocyte antigeninduced pluripotent stem celliPSC, induced pluripotent stem cellLSFM, light sheet fluorescence microscopyLVDd, left ventricular end-diastolic dimensionLVDs, left ventricular end-systolic dimensionLVEDV, left ventricular end-diastolic volumeLVEF, left ventricular ejection fractionLV, left ventricularMC, mural cellMI, myocardial infarctionSD, standard deviationtransplantationvWF, von Willebrand factorαMEM, alpha minimum essential medium

Identifiers

PMID36004071
PMCPMC9390608
OpenAlexW3202996756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.